SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

5 marketing jobs

NeoGenomics Laboratories logo
2 days ago

Marketing Analytics Manager

NeoGenomics Laboratories

USA (Remote)Full time
NeoGenomics Laboratories logo
2 days ago

Senior Marketing Campaign Operations Specialist

NeoGenomics Laboratories

USA (Remote)Full time
NeoGenomics Laboratories logo
2 weeks ago

Marketing Manager, MRD

NeoGenomics Laboratories

USA (On-site)Full time
NeoGenomics Laboratories logo
2 weeks ago

Director, Product Marketing

NeoGenomics Laboratories

USA (On-site)Full time
NeoGenomics Laboratories logo
5 months ago

Vice President, Global Marketing

NeoGenomics Laboratories

Fort Myers, FL (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
NeoGenomics Laboratories logo

Marketing Analytics Manager

NeoGenomics Laboratories

USA (Remote)

In-houseFull-timeSenior level8+ years exp.
2 days ago
NeoGenomics Laboratories logo

Senior Marketing Campaign Operations Specialist

NeoGenomics Laboratories

USA (Remote)

In-houseFull-timeSenior level5+ years exp.
2 days ago
NeoGenomics Laboratories logo

Marketing Manager, MRD

NeoGenomics Laboratories

USA (On-site)

$91K/yr - $113K/yr (Est.)In-houseFull-timeSenior level8+ years exp.
2 weeks ago
NeoGenomics Laboratories logo

Director, Product Marketing

NeoGenomics Laboratories

USA (On-site)

In-houseFull-timeDirector/executive10+ years exp.
2 weeks ago
NeoGenomics Laboratories logo

Vice President, Global Marketing

NeoGenomics Laboratories

Fort Myers, FL (On-site)

In-houseFull-timeSenior level15+ years exp.
5 months ago
NeoGenomics Laboratories logo
NeoGenomics Laboratories

Marketing Analytics Manager

USA (Remote)

Salary Not AvailableSenior Level8+ years expFull time

Posted 2 days ago

  • Job
  • Company
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the marketing attribution and reporting platform, drive data quality and actionable insights, and collaborate with leadership to align analytics with commercial KPIs while pursuing ongoing improvements in tools and practices.

  • Lead platform selection and implementation
  • Ensure data quality and trust in reporting
  • Translate data into strategic recommendations and drive investment decisions

Job Description

Responsibilities

  • Select, implement, and own the marketing attribution and reporting platform, evaluating solutions such as Marketing Cloud Intelligence while leveraging NeoGenomics' existing Salesforce and Marketing Cloud investments.
  • Establish and maintain data quality standards for marketing reporting, including campaign tagging, UTM parameters, and channel definitions. Proactively identify and resolve gaps before they undermine trust in reporting.
  • Build and maintain dashboards that connect marketing spend to leads, MQLs, SQLs, and pipeline contribution, providing visibility into performance across teams.
  • Translate data findings into clear, actionable recommendations regarding where to increase investment, optimize resources, or adjust strategy.
  • Partner with the Director of Marketing Operations and Commercial Enablement to ensure marketing data remains aligned with commercial KPIs and business objectives.
  • Monitor the organization's progress toward developing the data volume, consistency, and historical benchmarks required to support future marketing mix modeling initiatives.
  • Advise leadership on readiness, implementation options, and potential partnerships related to marketing mix modeling capabilities.
  • Continuously evaluate and adopt more efficient analytics tools and best practices, including AI-enabled technologies, to improve reporting accuracy, productivity, and business insights.

Requirements

  • Bachelor's degree required; Master's degree preferred.
  • Minimum of 8 years of experience in marketing analytics, marketing reporting, or marketing technology (MarTech), including hands-on experience with attribution platforms and Salesforce data.
  • Demonstrated success selecting, implementing, and managing marketing attribution or analytics platforms.
  • Proven ability to identify and resolve data quality challenges, including inconsistent campaign tagging, broken UTM tracking, and misaligned channel definitions.
  • Strong ability to transform complex data into clear, actionable business recommendations rather than simply reporting metrics.
  • Experience querying data directly using SQL or similar tools to answer business questions and diagnose data quality issues.
  • Working knowledge of Customer Data Platform (CDP) concepts and the ability to translate business requirements into accurate data specifications.
  • Familiarity with marketing mix modeling principles and data requirements, including the ability to advise stakeholders on organizational readiness and potential implementation options.
  • Comfortable evaluating and adopting emerging analytics tools and practices, including AI-enabled technologies, to drive efficiency and innovation.
  • Travel Requirements: Ability to travel as required for the role, up to 15% of the time, primarily for internal meetings and occasional conferences.

Preferred

  • Master's degree preferred

Benefits

  • competitively priced health plan options, including HMO and PPO
  • tuition reimbursement
  • Leadership development programs
  • wellness initiatives
  • highly engaged employee resource groups
  • Employees start with 16 days of paid time off, plus company holidays
  • company-matched 401(k), and an Employee Stock Purchase Program
NeoGenomics Laboratories logo

NeoGenomics Laboratories

3.2 Glassdoor

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom.

Founded in 2002
Fort Myers, Florida, USA
1.7K employees (24 in marketing)
neogenomics.com
53% recommend to a friend
56% CEO approval

Marketing Team

Marketing Team Size
17 (1% of company)
Median Career Experience
18 years
Median Tenure
4.1 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Preeti Saini, PhD
Director, Marketing
At the company for 2 years 1 month

Funding

Total Funding
$925.9M
Last Raise
$200M
Post IPO Equity, 5 years ago

Funding History

  • May 2021
    Post IPO Equity • $200M
  • Apr 2020
    Post IPO Equity • $125.4M
  • Apr 2020
    Post IPO Debt • $175M

Traffic Signals

Monthly Visitors
38.3K
Monthly Google Ads Budget
$3.1K
Traffic Source Mix
Search
48.2%
Direct
44.5%
Referral
6.1%
Social
0.6%
Paid
0.5%

Headcount Trend

Current headcount: ~1.7K

Recent News

NeoGenomics (NASDAQ: NEO) spotlights RaDaR 1.0 ctDNA trials at SABCS 2025
Dec 10, 2025 • Stock Titan
NeoGenomics (NASDAQ: NEO) to present real-world myeloid CGP data at ASH 2025
Dec 8, 2025 • Stock Titan
Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Dec 5, 2025 • Yahoo Finance
Franklin Resources Inc. Acquires 12,381 Shares of NeoGenomics, Inc. $NEO
Nov 30, 2025 • Defense World
NeoGenomics at Stephens Conference: Strategic Growth Amid Pharma Challenges
Nov 19, 2025 • Investing.com
NeoGenomics to Participate in Upcoming Investor Conferences
Nov 6, 2025 • Yahoo Finance
NeoGenomics to Participate in Upcoming Investor Conferences
Nov 6, 2025 • Business Wire
NeoGenomics (NASDAQ: NEO) presents RaDaR ST study in 166 patients, 15 tumor types
Oct 30, 2025 • Stock Titan
NeoGenomics’s (NASDAQ:NEO) Q3 Sales Top Estimates, Stock Soars
Oct 28, 2025 • The Globe and Mail
NeoGenomics: Q3 Earnings Snapshot
Oct 28, 2025 • San Francisco Chronicle
NeoGenomics Reports Third Quarter 2025 Results
Oct 28, 2025 • Business Wire
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
Oct 14, 2025 • Business Wire
NeoGenomics (NEO): Exploring Current Valuation After Recent Share Price Volatility
Sep 28, 2025 • Yahoo Finance
Here’s Alger Weatherbie Specialized Growth Fund’s Comment on NeoGenomics (NEO)
Sep 24, 2025 • Yahoo Finance
NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026
Sep 17, 2025 • Benzinga.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
Sep 13, 2025 • PR Newswire
Chris Smith new CEO of Laborie
Sep 11, 2025 • News Powered by Cision
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
Sep 10, 2025 • Morningstar.com
Brown Advisory Small-Cap Growth Strategy Sold Neogenomics (NEO) Following the News of CEO Departure
Sep 4, 2025 • Yahoo Finance
Following IP Win Against Natera, NeoGenomics Back on Track for Radar MRD Commercialization
Sep 3, 2025 • GenomeWeb
MoFo helps NeoGenomics secure cancer test kit patent infringement win against rival Natera
Sep 2, 2025 • The Global Legal Post
Fort Myers cancer lab firm wins federal patent lawsuit
Sep 2, 2025 • Business Observer
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire UK
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • Canada NewsWire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire
Court Invalidates Patent Claims: Natera's Legal Battle with NeoGenomics Takes New Turn, Core Patent Stands
Aug 29, 2025 • Stock Titan
NeoGenomics Scores Win In Natera DNA Test Patent Suit
Aug 29, 2025 • Law360
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
Aug 29, 2025 • Business Wire
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
Aug 29, 2025 • PharmiWeb
SentinelOne, Autodesk, Dollar Tree
Aug 29, 2025 • Reuters
NeoGenomics announces court ruling in its favor in lawsuit against Natera
Aug 29, 2025 • thefly.com
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
Aug 29, 2025 • MarketScreener
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
Aug 29, 2025 • Benzinga.com
Natera Provides Update on Patent Litigation with NeoGenomics
Aug 29, 2025 • Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
Aug 9, 2025 • Morningstar.com
Hemato Oncology Testing Market Size to Hit USD 15.72 Billion by 2034
Aug 5, 2025 • BioSpace
Laboratory Developed Tests Market to Surpass USD 23.03 Billion by 2032, Fueled by Precision Medicine and Rising Diagnostic Complexity – SNS Insider
Aug 5, 2025 • SNS Insider pvt ltd
Earnings Release: Here's Why Analysts Cut Their NeoGenomics, Inc. (NASDAQ:NEO) Price Target To US$8.72
Aug 1, 2025 • Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
Aug 1, 2025 • Pomerantz LLP
New Products Posted to GenomeWeb: Quanterix, Illumina, NeoGenomics, New England Biolabs, Touchlight
Aug 1, 2025 • GenomeWeb
NeoGenomics Second Quarter 2025 Earnings: EPS Misses Expectations
Jul 31, 2025 • simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
Jul 31, 2025 • PR Newswire
Fort Myers-based NeoGenomics sees stock plunge after reporting mixed results for Q2
Jul 30, 2025 • The News-Press
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
Jul 30, 2025 • Business Wire
NeoGenomics Reports Second Quarter 2025 Results
Jul 30, 2025 • BioSpace
BTIG Cuts Rating on NeoGenomics Stock
Jul 30, 2025 • GenomeWeb
NeoGenomics Reports Second Quarter 2025 Results
Jul 29, 2025 • Business Wire
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8%
Jul 29, 2025 • TradingView
NeoGenomics Clinical Revenue Soars 16% Despite Pharma Headwinds: Key Q2 Earnings Insights
Jul 29, 2025 • Stock Titan
NeoGenomics Q2 revenue up 10% but misses estimates as pharma revenue drags
Jul 29, 2025 • MarketScreener
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Jul 29, 2025 • Benzinga.com
NeoGenomics Seeks to Reassure Investors After Slashing Full-Year Guidance
Jul 29, 2025 • GenomeWeb
NeoGenomics Wants Jury Trial In Natera DNA Test Patent Fight
Jul 28, 2025 • Law360
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth
Jul 25, 2025 • Research and Markets
Clinical Oncology Next Generation Sequencing Market Size to Reach USD 2,129.82 Million By 2034
Jul 16, 2025 • BioSpace
U.S. Gastric Cancer Diagnostics Market Size, Share and Growth Report 2034
Jul 7, 2025 • BioSpace
Here’s Why NeoGenomics (NEO) Sold Off in Q1
Jul 2, 2025 • Yahoo Finance
Adaptive Biotechnologies Eyes Community Adoption of MRD Assay With Flatiron Health Integration
Jul 2, 2025 • GenomeWeb
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Jul 1, 2025 • Yahoo Finance
Minimal Residual Disease Testing Market Analysis 2025 – Insights For Long-Term Investment & Planning
Jul 1, 2025 • EIN Presswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Jul 1, 2025 • MarketScreener
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Jul 1, 2025 • BioSpace
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Jul 1, 2025 • Business Wire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
Jul 1, 2025 • Morningstar.com
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
Jun 30, 2025 • Business Wire
Companion Diagnostic Markets Report 2025-2029: The Future of Diagnostics by Application, Technology and Funding with Executive & Consultant Guides - ResearchAndMarkets.com
Jun 6, 2025 • Business Wire
Flow Cytometry in Oncology and Immunology Market Research 2025 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F
Jun 5, 2025 • Research and Markets
NeoGenomics at William Blair Conference: Strategic Growth and Innovation
Jun 3, 2025 • Investing.com
NeoGenomics (NEO) Debuts PanTracer Family of Genomic Profiling Tests
May 28, 2025 • StreetInsider.com
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
May 28, 2025 • Business Wire
NeoGenomics launches rapid c-MET diagnostic test for NSCLC
May 22, 2025 • Investing.com
Earnings Scheduled For May 9, 2025
May 9, 2025 • Benzinga.com
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight
May 7, 2025 • DelveInsight Business Research LLP
NeoGenomics Stock: Is It the Right Time to Buy?
May 1, 2025 • StocksToTrade
NeoGenomics Pays Off 1.25% Convertible Senior Notes
May 1, 2025 • Business Wire
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Apr 30, 2025 • Benzinga.com
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
Apr 30, 2025 • BioSpace
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Apr 30, 2025 • Benzinga.com
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops
Apr 29, 2025 • Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
Apr 29, 2025 • PR Newswire
Fort Myers-based NeoGenomics sees a strong start to 2025, with more growth expected this year
Apr 29, 2025 • Naples Daily News
North American Morning Briefing: Stock Futures -2-
Apr 29, 2025 • Morningstar.com
Other news to note for April 29, 2025
Apr 29, 2025 • BioWorld Financial Watch
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
Apr 22, 2025 • BioSpace
Alliancebernstein L.P. Sells 10,157 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Apr 16, 2025 • Defense World
Geode Capital Management LLC Has $49.99 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Apr 14, 2025 • Defense World
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
Apr 8, 2025 • StreetInsider.com
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
Apr 8, 2025 • Morningstar.com
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
Apr 8, 2025 • Business Wire
NeoGenomics Completes Acquisition of Pathline
Apr 7, 2025 • Business Wire
Other news to note for April 7, 2025
Apr 7, 2025 • BioWorld Financial Watch
Cancer Diagnostics: Market Overview, Dynamics, Top Trends, and Regional Insights
Apr 7, 2025 • PharmiWeb
Europe Biopsy Devices Market Report 2025-2033 Featuring BD and Co, Thermo Fisher Scientific, Bio-Rad, Exact Sciences, Biocept, Roche, Myriad Genetics, Qiagen, NeoGenomics, Quest Diagnostics
Apr 2, 2025 • Research and Markets
Appointments and advancements for April 1, 2025
Apr 1, 2025 • BioWorld Financial Watch
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
Apr 1, 2025 • Business Wire
NeoGenomics Appoints Tony Zook Chief Executive
Apr 1, 2025 • MarketScreener
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
Apr 1, 2025 • BioSpace
Fort Myers-based NeoGenomics expands cancer testing reach with acquisition
Mar 11, 2025 • The News-Press
NeoGenomics expands with Pathline acquisition
Mar 10, 2025 • Investing.com
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
Mar 10, 2025 • Business Wire

Links

neogenomics.comLinkedInX (Twitter)Crunchbase